Low Molecular Weight Heparin
Keywords:
-Abstract
-
Downloads
References
Duclos JP(1984). L heparine, Fabircation, Structure, Proprietes, Analyses, Masson, Paris.
Huang JN, Shimamura A. Low-Molecular-Weight Heparins. Hematol Oncol Clin North Am 1998;12:1251-81.
Caranobe C, Barret A, Gabaig AM, et al. Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits. Thromb Res 1985;40:129-33.
Rosenberg RD. Biochemistry and pharmacology of low molecular weight heparin. Semin Hematol 1997;34:2-8.
Aguilar D, Goldhaber SZ. Clinical uses of low-molecular-weight heparins. Chest 1999;115:1418-23.
Fareed J, Walenga JM, Hoppenstead D, et al. Comparative study on the in vitro and in vivo activities of seven low molecular weight heparins. Haemostasis 1988;18:3.
Choy JB, Armstrong PW. Anticoagulant therapy in unstable angina. Cardiol Clin 199999;17:327-43.
Hull RD, Raskob GE, Pineo G, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-5.
Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541-6.
Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72:186-90.
Fiessinger J, Lopez-Fernandez M, Gatterer E, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996;76:195-9.
Dunn AS, Coller B. Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med 1999;106:660-9.
Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 19999;130:800-9.
Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996;334:682-7.
Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
Yusen RD, Haraden BM, Gage BF, Woodwar Rubin BG, Botney MD. Criteria for outpatient management of proximal lower extremity deep venous thrombosis. Chest 1999;115:972-9.
Clark S. Current issues in management of thrombosis. Lancet 1995;346:113-4.
Meyer G, Brenot F, Pacouret G, et al. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute nonmassive pulmonary embolism: an open randomized pilot study. Thromb Haemost 1995;74:1432-5.
Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-9.
The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-62.
Tung C, Sauri D, Fintel D, Gheorghiade M. Management of high-risk subsets in unstable angina. Cardiol Clin 1999;17:415-37.
Choy JB, Armstrong PW. Anticoagulant therapy in unstable angina. Cardiol Clin 1999;17:327-43.
Kay R, Wong KS, Yu UL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;3333:1588-93.
Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost 1990;16:12-8S.
Weitz JI. Low molecular weight heparins. N Eng J Med 1997;337:688-98.
Abbate R, Gori AM, Farsi A, Attanasio M, Pepe G. Monitoring of low-molecular-weight heparins in cardiovascular disease. Am J Cardiol 1998,82:33L-36L.
Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with lowmolecular-weight heparin. A meta-analysis. Arch Intern Med 1995;155:601-7.
Leizorovicz A, Simonneau G, Decousus H, Boessel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-anlysis, et al. Br Med J 1994;309:299-304.
Kakkar VV. Efficacy and safety of Clivarin and other LMWH's in general surgery: a meta-analysis. Blood Coagul Fibrinolysis 1993;4:523-7.
Hieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Blood 1991;78:2337-43.
Holst J, Lindblad B, Bergqvist D, et al. Protamine neutralization of intravenous and subcutaneous low molecular weight heparin (Tinzaparin, Logiparin). An experimental investigation in healthy volunteer. Blood Coagul Fibrinolysis 1994;5:795-803.
Van Ryn-Mckenna J, Cai L, Ofosu Fa, Hirsh J, Buchanan MR. Neutralization of enoxaparin-induced bleeding by protamine sulfate. Thromb Haemost 1990;63:271-4.
Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight-heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114:489S-510S.
Fureder W, Kyrle PA, Gisslinger H, Lechner K. Low-molecular-weight heparin-induced skin necrosis. Ann Hematol 1998;77:127-30.
Kessler CM. Low molecular weight heparins: Practical considerations. Semin Hematol 1997;34:35S-42S.
Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindication to coumarin. Thromb Haemost 1994;71:7-11.
Melissari E, Parker CJ, Wilson NV, et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992;68:652-6.
Hirsh J, Raschke R, Warkentin TE, et al. Heparin: Mechanism of action, pharmacokinetics, dosing, considerations, monitoring, efficacy, and safety. Chest 1995;108:258S-75S.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
